Millipore Corporation (MIL), a leading life science company, and Merck KGaA, the Germany-based pharmaceutical and chemicals company, entered into a definitive agreement under which Merck will acquire all outstanding shares of common stock of Millipore for US$107 per share in cash, or a total transaction value Incorporatedluding net debt, of approximately €5.3 billion (US$7.2 billion).

MercK KGaA, also called the German Merck or Merck Dermstadt is one of the oldest chemical and pharmaceutical companies in the world. The company lost its foreign assets following the First World War Incorporatedluding its U.S. subsidiary that eventually became Merck & Company (MRK). Since Merck & Company holds the rights to the Merck name in the U.S., Merck KGaA operates here under the name EMD Chemicals (EMD stands for Emanuel Merck, Dermstadt). Merck KGaA was privately owned until 1995 when it went public in Germany. However, the Merck family remains its controlling shareholder.

The transaction was approved by the boards of directors of both companies. Millipore and Merck will create a €2.1 billion (US$2.9 billion) world-class partner in the life science sector, achieving significant scale in high-margin specialty products with an attractive growth profile.

Together, Millipore and Merck will have a significant presence in high-growth segments and an enhanced geographic presence. Combining the research and development capabilities of both companies will create a powerful innovation platform to develop cutting-edge technologies that are tailored even more closely to the needs of customers.

The acquisition will be funded through available cash and a term loan provided by Bank of America, Merrill Lynch, BNP Paribas and Commerzbank Aktiengesellschaft. Merck plans to replace part of the facility by issuing bonds later. Merck is committed to retaining a solid investment-grade rating.

Millipore has a strong position in the attractive bioresearch and bio-production segments, offering a comprehensive range of products, technologies and services for pharma and biotech companies, as well as for academia, to improve laboratory productivity and develop and optimize manufacturing processes.

Millipore has been continuously transforming itself into a life science leader by driving innovation, entering new markets and generating exceptional operational performance. In 2009, Millipore generated sales of US$1.7 billion, with around 6,000 employees in more than 30 countries. The transaction is expected to be completed by the second half of 2010.

We are reissuing this article to correct a mistake. The original article, issued earlier today, should no longer be relied upon.

Zacks Investment Research

1. (MIL) Millipore Corporation’s Earnings Report Tops EstimatesMillipore Corp. (MIL) reported fourth-quarter earnings per share of $1.00, seven cents above the Zacks...
2. (MRK) Merck Aims to Expand GardasilRecently, Merck (MRK) submitted study data to the US Food and Drug Administration (FDA) related...
3. (MIL) Millipore Corporation Buys Remaining Stake in IndiaMillipore Corp. (MIL) yesterday announced the acquisition of the remaining 60% ownership of its joint-venture...
4. (MIL) Millipore Corporation Falls Short of EstimatesMillipore Corp. (MIL) reported third-quarter earnings per share of 71 cents, well below the Zacks...
5. (MRK) Merck and Schering-Plough Earn Merger ApprovalRecently, Merck (MRK) and Schering-Plough (SGP) received approval from the US Federal Trade Commission [FTC],...
6. (GPRO) Millipore & Roka to CollaborateOn Monday, Millipore Corp. (MIL) announced its collaboration with Roka Bioscience Inc. to develop molecular...

Search Posts by Tag: Merck & Company Inc | MIL | Millipore Corporation | MRK | Scientific & Technical Instruments | Technology

RSS Feeds by Tag: Merck & Company Inc | MIL | Millipore Corporation | MRK | Scientific & Technical Instruments | Technology |

Other Posts by: vitalstocks | RSS Feed for this author